A NIAID-sponsored clinical trial of an mpox vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults, according to interim study results presented at the IDWeek2024 conference in Los Angeles. Adolescents are among the population groups affected by mpox in the current Clade I outbreak. The authors underscored the need to evaluate the vaccine in younger children to extend the evidence base to all people affected by mpox.
Mpox Vaccine Is Safe and Generates a Robust Antibody Response in Adolescents
Latest News
Latest news about the results of the COVAIL trial regarding the Sanofi booster. GW participated as one of the many sites for this COVID-19 vaccine study.
The GW VRU contributed critical data needed to approve the use of the Mpox vaccine in adolescents. This is of huge importance given the current Mpox outbreak has yet to be controlled and has disproportionately impacted children in this wave.
Our Deputy Director, Dr. Elissa Malkin, was a part of the Pfizer's newest study on its respiratory syncytial virus (RSV) vaccine, Abrysvo, which has shown to have a strong immune response in adults 18+.